¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"stable plasma protein solution"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹éÁú
  • carrier protein
    ¿î¹Ý´Ü¹éÁú
  • catabolite (gene) activator protein
    ºÐÇØ´ë»ç»ê¹°(À¯ÀüÀÚ)Ȱ¼º´Ü¹éÁú
  • catabolite activator protein
    ºÐÇØ´ë»ç»ê¹°È°¼º´Ü¹éÁú
  • denatured protein
    º¯¼º´Ü¹éÁú
  • derived protein
    À¯µµ´Ü¹éÁú
  • different membrane protein
    À¯°ü¸·´Ü¹éÁú
  • extracellular matrix protein
    ¼¼Æ÷¹Ù±ù¹ÙÅÁÁú´Ü¹éÁú, ¼¼Æ÷¿Ü±âÁú´Ü¹éÁú
  • endogenous protein
    ³»ÀδܹéÁú
  • foreign protein
    ÀÌÁ¾´Ü¹éÁú
  • glial fibrillary acidic protein
    ¾Æ±³¼¼Æ÷¼¶À¯»ê¼º´Ü¹éÁú, ±³¼¶À¯»ê¼º´Ü¹éÁú
  • globular protein
    °ø¸ð¾ç´Ü¹éÁú, ±¸»ó´Ü¹éÁú
  • heat-shock protein
    ¿­Ãæ°Ý´Ü¹éÁú
  • heterologous protein
    ÀÌÁ¾´Ü¹éÁú
  • high-protein diet
    °í´Ü¹éÁú½Ä»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • bromine solution
    ºê·Ò¿ë¾×
  • buffer solution
    ¿ÏÃæ¾×
  • cardioplegic solution
    ½ÉÀåÁ¤Áö¾×, ½ÉÀ帶ºñ¾×
  • colloid solution
    ÄÝ·ÎÀ̵å¿ë¾×, ±³Áú¿ë¾×
  • conjugate solution
    ¦¿ë¾×
  • crystalloid solution
    Á¤Áú¾×
  • culture solution
    ¹è¾ç¾×
  • decontaminating solution
    ¿À¿°Á¦°Å¿ë¾×
  • disclosing solution
    Ä¡ÅÂÂø»ö¾×
  • equimolecular solution
    µîºÐÀÚ¿ë¾×
  • etching solution
    ºÎ½Ä¿ë¾×
  • half-normal solution
    ¹Ý±ÔÁ¤¾×
  • heavy solution
    Áß¾×
  • hydrogen peroxide solution
    °ú»êÈ­¼ö¼Ò¼ö
  • hyperbaric solution
    °íºñÁß¿ë¾×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • principal outer membrane protein (POMP)
    ÁÖ¿ä¿Ü¸·´Ü¹éÁú
  • prosthetic protein
    ¹èÇÕ¼º ´Ü¹é(ÛÕùêàõÓ±ÛÜ).
  • protein
    ´Ü¹éÁú
  • protein
    ´Ü¹é(Ó±ÛÜ), ´Ü¹éÁú(Ó±ÛÜòõ)
  • protein
    ´Ü¹é(Áú)
  • protein 3
    ´Ü¹é 3
  • protein 4.1
    ´Ü¹é 4.1
  • protein A
    ´Ü¹éÁú A (Æ÷µµ±¸±ÕÀÇ)
  • protein C
    C ´Ü¹é
  • protein score
    ´Ü¹é°¡(ËÀËÑ˧) ½ÄǰÀÇ .
  • protein sensitization
    ´Ü¹é°¨ÀÛ(¡­ÊïíÂ).
  • protein separation
    ´Ü¹éºÐ¸®
  • protein sparing effect
    ´Ü¹éÁúÀý¾àÈ¿°ú(Ó±ÛÜòõï½å³üùÍý).
  • protein synthesis
    ´Ü¹éÁúÇÕ¼º.
  • protein synthesis factor
    ´Ü¹éÇÕ¼ºÀÎÀÚ(Ó±ÛÜùêà÷ì×í­).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • spinning solution
    ¹æ»ç¾×(Û·Þêäû).
  • standard solution
    Ç¥ÁØ¿ë¾×(øöñÞéÁäû).
  • stock solution
    ¿ø¾×(ê«äû).
  • stop solution
    Á¤Áö¾×.
  • supersaturated solution
    °úÆ÷È­¾× (Φøéûúäû).
  • tribromoethanol solution
    Æ®¸®ºê·Î¸ð¿¡Åº¿Ã¾×(¡­äû).
  • turmeric test solution
    °­È²½ÃÇè¾× (¡­ãËúÐäû).
  • unsaturated solution
    ºÒÆ÷È­¾×(¡­äû).
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (¡­úìíì).
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (?Ì´Ëö).
  • blood plasma
    Ç÷Àå
  • blood plasma substitute
    ´ë¿ë(ÓÛéÄ)Ç÷Àå.
  • citrated normal human plasma
    Á¤»óÀα¸¿¬»ê¿°Ã·°¡Ç÷Àå.
  • coagulase plasma
    ÄھƱֶóÁ¦ Ç÷Àå
  • effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • competitive protein-binding technique
    °æÇÕÀû ´Ü¹éÁú °áÇÕ¼ú(ÌæùêîÜÓ±ÛÜòõÌ¿ùêâú)
  • complete protein
    ¿ÏÀü´Ü¹éÁú(èÇîïÓ±ÛÜòõ)
  • conjugated protein
    Á¢ÇմܹéÁú(ïÈùêÓ±ÛÜòõ)
  • contractile protein
    ¼öÃ༺ ´Ü¹éÁú(â¥õêàõÓ±ÛÜòõ)
  • copper protein
    µ¿´Ü¹éÁú(ÔÞÓ±ÛÜòõ)
  • core protein
    ÇٽɴܹéÁú(ú·ãýÓ±ÛÜòõ)
  • corticosteroid-binding protein
    "ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ), (ÔÒ) transcortin"
  • cortisol-binding protein
    ÄÚÆ¼¼Ö°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ) (ÔÒ) transcortin
  • C-protein
    C ´Ü¹éÁú (Ó±ÛÜòõ)
  • C-reactive protein
    C¹ÝÀÀ(Úãëë) ´Ü¹éÁú(Ó±ÛÜòõ)
  • CRO protein
    CRO ´Ü¹éÁú (Ó±ÛÜòõ)
  • crystal protein
    °áÁ¤ ´Ü¹éÁú(Ì¿ïÜÓ±ÛÜòõ)
  • cyclic AMP receptor protein
    °í¸®AMP ¼ö¿ëü ´Ü¹éÁú(áôé»ô÷Ó±ÛÜòõ)
  • delipidized protein
    Å»Áö´Ü¹éÁú(÷­ò·Ó±ÛÜòõ)
  • derived protein
    À¯µµ´Ü¹éÁú(ë¯ÓôÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
PEP peptidase; phospho(enol)pyruvate; peer evaluation program; phosphoenolpyruvate; pigmentation, edema,...
PPP pain perception profile; palatopharyngoplasty; palmoplantar pustulosis; pentose phosphate pathway; p...
SBP schizobipolar; serotonin-binding protein; spontaneous bacterial peritonitis; steroid-binding plasma ...
L/P lactate/pyruvate [ratio]; liver plasma [concentration]; lymph/plasma [ratio]
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
LRS Lactated Ringer's Solution
PSS Physiological saline solution
PEG-ELS Polyethylene glycol-electrolyte lavage solution
RL Ringer lactate solution
RL Ringer solution
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • solution tablet
    ¿ëÇØÁ¤
  • stock solution
    ¿ø¾×
  • strong ammonia solution
    °­ ¾Ï¸ð´Ï¾Æ¼ö
    ¹«»ö Åõ¸íÇÑ °­ ¾ËÄ®¸®¼º ¿ë¾×. 27¡­30%ÀÇ ¾Ï¸ð´Ï¾Æ¸¦ ÇÔÀ¯ÇÑ´Ù. ¿ë¸Å ¹× ¾Ï¸ð´Ï¾Æ¿øÀ¸·Î »ç¿ëµÈ´Ù.
  • supersaturated solution
    °úÆ÷È­ ¾×
    ¿µ±¸È÷ ÇÔÀ¯µÉ ¼ö ÀÖ´Â ¾ç ÀÌ»óÀÇ ¿ëÁúÀÌ ³ì¾Æ ÀÖ´Â ºÒ¾ÈÁ¤ÇÑ ¿ë¾×.
  • thymol solution
    Ƽ¸ô ¿ë¾×
  • toluidine blue solution
    toluidine blue ¿ë¾×
  • unsaturated solution
    ºÒÆ÷È­ ¾×
  • volumetric solution
    ¿ë·®¾×
    1 ¸®ÅÍ Áß¿¡ ¿ëÁúÀÇ ±×·¥ »ó´ç¼ö¸¦ ÇÔÀ¯ÇÏ´Â ¿ë¾×.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
plasma cell gingivitis Intense hyperaemic oedema and inflammation of the gingiva resulting from a hypersensitivity reaction. A dense plasma cell infiltrate is seen in the lamina propria.
Synonym: atypical gingivitis.
(05 Mar 2000)
plasma cell hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
plasma cell leukaemia An unusual disease characterised by leukocytosis and other signs and symptoms that are suggestive of leukaemia, in association with diffuse infiltrations and aggregates of plasma cells in the spleen, liver, bone marrow, and lymph nodes, and the presence of considerable numbers of plasma cells in the circulating blood; the total number of leukocytes in the latter may range from normal levels to 80,000 or 90,000 per cu mm, and 5 to 90% may be plasma cells; multiple myelomas are observed in some examples of plasma cell leukaemia, but discrete nodules are not formed in bone. Although there are other clinicopathologic differences in the two conditions, they may be phases of the same basic process.
(05 Mar 2000)
plasma cell mastitis A condition of the breasts characterised by tumourlike indurated masses containing numerous plasma cells, usually resulting from mammary duct ectasia; although clinically resembling malignant disease (attachment to skin and enlargement of axillary lymph nodes), it is not neoplastic.
(05 Mar 2000)
plasma cell myeloma Cells resemble mature or immature plasma cells with nuclei that appear cleaved or resemble immunoblasts. The tumour cells are CD19- , CD20- , CD22- and SIg- , but are also cIg+ and CD38+. The Ig heavy and light chain genes can be translocated or deleted. These neoplasms are often disseminated BM tumours of adults and progress to multiple myeloma.
(05 Mar 2000)
plasma cells Special white blood cells that produce antibodies.
(12 Dec 1998)
plasma containment <physics> In physics experiments or nuclear fusion experiments, operation is intended to prevent, in an effective and sufficiently prolonged manner, the particles of a plasma from striking the walls of the container in which this plasma is produced.
Plasma confinement is a fundamental requirement for obtaining net energy from a fusion plasma. The reason is that scattering (hence diffusion) is at least an order of magnitude more probable than fusion reactions. Hence, without confinement, the plasma fuel would disperse before enough fusion reactions could take place.
(31 Dec 1997)
plasma exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (ppf), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.
(12 Dec 1998)
plasma expander Artificial plasma extender.
(18 Nov 1997)
plasma factor X <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
plasma fibronectin A circulating a2-glycoprotein that functions as an opsonin, mediating reticuloendothelial and macrophage clearance of fibrin microaggregates, collagen debris, and bacterial particulates, protecting microvascular perfusion and lymphatic drainage.
(05 Mar 2000)
plasma focus <radiobiology> The Plasma Focus is another device which depends on the pinch effect. Possible applications include both fusion and plasma propulsion, as well as other plasma research.
In essence the plasma focus is generated by discharge of a current across the ends of two coaxial insulated conducting pipes. The Plasma Focus caused a huge stir when they generated copious neutrons, until it was discovered that the source of the neutrons was knockoffs from deuterium due to pinch accelerated electrons or ions. Plasma focus is sort of a point version of the Zpinch.
(09 Oct 1997)
plasma frequency <radiobiology> The natural collective oscillation frequency of a charge species (electrons, ions, etc.) in a plasma, in the absence of (or at least parallel to) a magnetic field. Also known as Langmuir or Langmuir-Tonks frequency.
See: electrostatic waves, plasma oscillations.
(09 Oct 1997)
plasma hydrolysate An artificial digest of protein derived from bovine blood plasma prepared by a method of hydrolysis sufficient to provide more than half of the total nitrogen present in the form of alpha-amino nitrogen; used when high protein intake is indicated and cannot be accomplished through ordinary foods.
See: protein hydrolysate.
(05 Mar 2000)
plasma kallikrein <protein> A plasma serine protease with an apple domain.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á